Accueil   Diary - News   All news ELSALYS BIOTECH concludes with THEA a license option agreement on its ELB011 program in ophthalmology

ELSALYS BIOTECH concludes with THEA a license option agreement on its ELB011 program in ophthalmology

  • ELB011, a first-in-class antibody program, demonstrates an anti-angiogenic effect on the formation of new blood vessels which cause certain retinal diseases including AMD (age-related macular degeneration)

 

  • THEA laboratories, a company specialized in ophthalmology, takes an exclusive license option for the development and commercialization of ELB011.

 

 

Lyon, FRANCE, 22 February 2018, ELSALYS BIOTECH, a new player in French immunooncology, has signed a license option agreement with THEA for the development of its ELB011 program in ophthalmology.

 

The option concerns the clinical development (expected from 2020) and the commercialization of ELB011, a new first-in-class antibody in the treatment of wet AMD and other retinal vascular pathologies. The innovative mechanism of action of ELB011 makes it possible to consider its development in monotherapy or in combination with anti-VEGF agents, the current standard of care for these pathologies, whose efficacy can diminish in the long term.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree